Thanks for the reply. Similar thoughts, if the 1B had thrown up some crazy good data, then I suspect it would have rated more than a poster session.
Still some mystery about the 1B results though. We have the numbers, but we don't know where the numbers fit into the cohorts. The ASCO poster mentioned LT dosing, but whether that's been in place for the earlier cohorts, I've no idea. We don't even know how many of the patients are still ok or whether the CR came from the third cohort or an earlier one. Hopefully we'll get some answers from the content of the poster. Possibly someone else has already seen some of the answers in a document I missed.
Cheers
IMU Price at posting:
2.0¢ Sentiment: None Disclosure: Held
(20min delay)
